Clinical Trials Logo

Angina, Unstable clinical trials

View clinical trials related to Angina, Unstable.

Filter by:

NCT ID: NCT00263263 Completed - Clinical trials for Coronary Artery Disease

RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.

Start date: September 2003
Phase: Phase 2
Study type: Interventional

Context: Sirolimus-eluting-stents have improved the benefits of percutaneous interventions in native coronary arteries reducing the occurrence of restenosis and repeated revascularization, however saphenous vein grafts have been always excluded form randomized trials. Objective: To evaluate the angiographic and clinical impact of sirolimus-eluting-stents with respect to bare-metal-stents in degenerated vein grafts. Design: Double-blind randomized controlled non-industry-sponsored trial. Setting: A single-center tertiary-care referral hospital. Patients: All patients are randomly allocated to sirolimus-eluting-stent implantation or the corresponding bare-metal-stent. All patients are followed clinically and repeated angiographic follow-up is performed in all at 6-months. Main outcome measure: Primary end-point is 6-months angiographic in-stent late loss. Secondary end-points include: binary angiographic in-stent and in-segment restenosis, intravascular-ultrasound-measured neo-intimal hyperplasia volume and all the clinical events (death, myocardial infarction, target-lesion and target-vessel revascularization).

NCT ID: NCT00250471 Completed - Unstable Angina Clinical Trials

PROTECT-TIMI 30 Trial

Start date: May 2003
Phase: Phase 3
Study type: Interventional

The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart attack and other cardiovascular complications who will undergo surgery to open up blocked arteries in the heart.

NCT ID: NCT00231738 Completed - Clinical trials for Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease

Protective Effect of EPA on Cardiovascular Events

Start date: November 1996
Phase: Phase 4
Study type: Interventional

The purpose of this study was to test the hypothesis that the long-term use of highly (>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.

NCT ID: NCT00222352 Completed - Angina, Unstable Clinical Trials

Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes

Dispo-ACS
Start date: December 2004
Phase: N/A
Study type: Observational

In a randomized, controlled clinical trial, point-of care testing at the bedside using the cardiac biomarker troponin I in ED patients with possible ACS will be compared to traditional testing of this assay for myocardial necrosis obtained in the central laboratory. Our hypothesis: point-of-care testing for troponin I will decrease the time for disposition of patients with possible ACS in the emergency setting and decrease the time required for administering appropriate therapies for these patients.

NCT ID: NCT00219674 Completed - Clinical trials for Myocardial Infarction

At-Home Automated External Defibrillator (AED) Training Study

Start date: July 2004
Phase: Phase 2
Study type: Interventional

The purpose of the research is to determine the best automated external defibrillator (AED) training approach for high-risk patients and their family members with regard to AED skills retention and psychological adjustment.

NCT ID: NCT00181818 Completed - Clinical trials for Myocardial Infarction

Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

Start date: October 1999
Phase: Phase 4
Study type: Interventional

The purpose of the study is to test the efficacy and safety of bupropion SR for smokers hospitalized with acute cardiovascular disease.

NCT ID: NCT00169975 Completed - Myocardial Ischemia Clinical Trials

Efficacy of the CMI Magnetocardiograph in Diagnosing Acute Coronary Syndromes in Patients Presenting With High Risk Unstable Angina.

Start date: August 2004
Phase: Phase 3
Study type: Observational

A magnetocardiograph (MCG) is a device capable of recording of magnetic fields arising from the electrical activity of the heart with traces similar to an electrocardiogram (ECG). This system was developed as a noninvasive, non-contact diagnostics of obstructive coronary artery disease (CAD), and especially of lack of oxygen in the heart as in a heart attack. The overall objective of this study is to demonstrate the efficacy of this MCG device for the detection and diagnosis of lack of oxygen of the heart in patients with chest pain.

NCT ID: NCT00139802 Completed - Clinical trials for Ischemic Heart Disease

DANish Multicenter STENT Trial

Start date: April 1997
Phase: Phase 4
Study type: Interventional

The purpose of the study was to evaluate procedural and late outcome of coronary artery stenting using 2 different unmounted stents

NCT ID: NCT00133003 Completed - Coronary Disease Clinical Trials

Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

Start date: March 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.

NCT ID: NCT00123565 Completed - Clinical trials for Coronary Atherosclerosis

Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction

SHINE
Start date: December 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, each in a group of about 180 patients per group to find which is the most adequate, versus heparin and glycoprotein IIbIIIa (GPIIBIIIA) antagonist.